Results 271 to 280 of about 472,035 (296)

Decreased incidence of skeletal-related events in mRCC

Nature Reviews Urology, 2014
Takeshi Yuasa, Shinji Urakami
openaire   +1 more source

The cost of treating skeletal-related events in patients with prostate cancer.

The American journal of managed care, 2008
To examine the economic burden of skeletal-related events (SREs) and to assess the frequency of different types of SREs in this population.Retrospective claims analysis.Data were obtained from i3's Lab Rx Database from May 1, 2000, through March 31, 2005. Patients included had at least 2 claims with a diagnosis of prostate cancer, at least 2 subsequent
Maureen J, Lage, Beth L, Barber, David J, Harrison, Sun, Jun   +3 more
openaire   +1 more source

Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events

Urologic Oncology: Seminars and Original Investigations, 2022
J Peter Marquardt, Bruce Montgomery
exaly  

Preventing Skeletal-Related Events in Multiple Myeloma

Oncology Times, 2018
openaire   +1 more source

Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases

Journal of Oncology Pharmacy Practice, 2021
openaire   +2 more sources

Skeletal Complications (Skeletal-Related Events)

2016
openaire   +1 more source

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European Journal of Cancer, 2012
Salvatore Siena, Fred Saad, Alison Stopeck   +2 more
exaly  

Skeletal-Related Events

2011
openaire   +1 more source

[Drug therapy for skeletal-related events].

Nihon rinsho. Japanese journal of clinical medicine, 2016
Satoru, Maruyama, Nobuo, Shinohara
openaire   +1 more source

Skeletal-Related Events

2008
openaire   +1 more source